Klinger H, Thompson G K, Stevens L M. "Method for the Synthesis of Doxapram Impurity 30" [P]. US Patent, US 10843352 B2, 2021-11-13.
参考文献 Literature
Xu M, Hu Y, Zhou D. "Development and Validation of an LC-MS/MS Method for the Determination of 多沙普仑杂质30 in Pharmaceutical Formulations". J. Pharm. Biomed. Anal., 2011, 1696, 6812-6817.
Jensen P, Larsen A M, Olsen K. "A Stability-Indicating HPLC Method for the Separation and Quantification of 多沙普仑杂质30 as an Impurity". Biomed. Chromatogr., 2012, 887, (10), 3599-3602.
O'Brien K, Kennedy M L. "Identification and Structural Characterization of a Novel Degradation Product of Doxapram Impurity 30 Using HRMS and NMR". Talanta, 2024, 1532, (9), 6223-6234.
Fischer P, Wagner E. "Forced Degradation Studies to Evaluate 多沙普仑杂质30 Profile in Drug Substances According to ICH Guidelines". Anal. Chem., 2025, 1073, 3998-4009.